ArticleFrontiers in immunology2026
Reduced-intensity post-cyclophosphamide-based graft-versus-host disease prophylaxis for umbilical cord blood transplantation: a single-center pilot study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-cyclophosphamide (PTCy)-based GVHD prophylaxis has shown significant success in haploidentical transplants. The potential of PTCy in adult umbilical blood transplantation (UCBT) remains unclear due to concerns about engraftment, given the limited number of CD34+ cells. This study aimed to explore the preliminary safety and efficacy of a reduced-intensity PTCy (RI-PTCy) in single-unit UCBT in adults. Methods: A total of 52 adult patients who underwent a single-unit UCBT were included in this pilot study. Patients were divided into three groups based on GVHD prophylaxis regimens: No PTCy (n=30), 100 mg RI-PTCy (n=15), and 400 mg RI-PTCy (n=7). Safety and efficacy were investigated post-transplantation. Results: The median times for neutrophil engraftment were 15 days (range, 12-27 days) in the No PTCy group, 16 days (range, 13-25 days) in the 100 mg RI-PTCy group, and 18 days (range, 15-24 days) in the 400 mg RI-PTCy group. Platelet engraftment occurred at 30 days (range, 21-77 days), 32 days (range, 18-40 days), and 31 days (range, 25-42 days), respectively. By day +100, the RI-PTCy groups had a significantly lower cumulative incidence of grade II-IV aGVHD than the No PTCy group. The cumulative incidence of grade II-IV aGVHD was 30.0% (95% CI, 13.6%-46.4%) in the No PTCy group, compared with 6.7% (95% CI, 0%-19.3%) in the RI-PTCy 100 mg group and 0% in the RI-PTCy 400 mg group (P = .044). Notably, the 400 mg RI-PTCy group presents a higher incidence of 28-day bloodstream infection. Moreover, the estimated 1-year GRFS were 53.3% (95% CI, 34.3%-69.1%), 71.1% (95% CI, 39.4%-88.3%), and 100.0% in the No PTCy group, the 100 mg and 400 mg RI-PTCy groups (P = .059). Conclusions: RI-PTCy appears promising as a GVHD prophylaxis strategy in this exploratory pilot cohort; these hypothesis-generating findings warrant validation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.